Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Sep;29(9):515-21.
doi: 10.1038/jhh.2014.125. Epub 2015 Jan 29.

The renin-angiotensin-aldosterone system and calcium-regulatory hormones

Affiliations
Review

The renin-angiotensin-aldosterone system and calcium-regulatory hormones

A Vaidya et al. J Hum Hypertens. 2015 Sep.

Abstract

There is increasing evidence of a clinically relevant interplay between the renin-angiotensin-aldosterone system and calcium-regulatory systems. Classically, the former is considered a key regulator of sodium and volume homeostasis, while the latter is most often associated with skeletal health. However, emerging evidence suggests an overlap in regulatory control. Hyperaldosteronism and hyperparathyroidism represent pathophysiologic conditions that may contribute to or perpetuate each other; aldosterone regulates parathyroid hormone and associates with adverse skeletal complications, and parathyroid hormone regulates aldosterone and associates with adverse cardiovascular complications. As dysregulation in both systems is linked to poor cardiovascular and skeletal health, it is increasingly important to fully characterize how they interact to more precisely understand their impact on human health and potential therapies to modulate these interactions. This review describes the known clinical interactions between these two systems including observational and interventional studies. Specifically, we review studies describing the inhibition of renin activity by calcium and vitamin D, and a potentially bidirectional and stimulatory relationship between aldosterone and parathyroid hormone. Deciphering these relationships might clarify variability in outcomes research, inform the design of future intervention studies and provide insight into the results of prior and ongoing intervention studies. However, before these opportunities can be addressed, more effort must be placed on shifting observational data to the proof of concept phase. This will require reallocation of resources to conduct interventional studies and secure the necessary talent.

PubMed Disclaimer

Figures

None
Interactions between the renin-angiotensin-aldosterone system and calcium-regulatory hormones
The 1,25(OH)2D-VDR complex, and calcium ion, can decrease plasma renin activity either by decreases renin expression or decreasing renin secretion, respectively. Some evidence has shown that PTH may directly increase renin secretion in the acute setting. Aldosterone and angiotensin II stimulate the secretion of PTH via the MR and AT1R; the former with chronic exposure whereas the latter in the acute setting. PTH, in turn, has been implicated as an aldosterone secretagogue via interactions with the PTH-R in the adrenal zona glomerulosa. 25(OH)D=25-hydroxyvitamin D 1,25(OH)2D=1,25-dihydroxyvitamin D VDR=vitamin D receptor PTH=parathyroid hormone Ca2+=calcium cation CaSR=calcium sensing receptor MR=mineralocorticoid receptor AT1R=angiotensin receptor type 1 ACE=angiotensin converting enzyme

References

    1. Laragh JH, Sealey JE. The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure. Am J Hypertens. 2011;24(11):1164–80. - PubMed
    1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17. - PubMed
    1. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145–53. - PubMed
    1. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–81. - PubMed
    1. Bilezikian JP, Brandi ML, Rubin M, Silverberg SJ. Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. Journal of internal medicine. 2005;257(1):6–17. - PubMed

Publication types